News >

NICE Recommends Against Frontline Osimertinib in EGFR-Mutant NSCLC

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 23, 2020

lung cancer
The United Kingdom’s National Institute for Health and Care Excellence (NICE) will not recommend osimertinib (Tagrisso) as a frontline treatment for patients with locally advanced or metastatic EGFR-mutant non–small cell lung cancer (NSCLC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication